Novavax Inc on Tuesday delayed the beginning of a late-stage US trial of its experimental coronavirus vaccine by roughly a month to the tip of November, citing delays in scaling up the manufacturing course of.
The US-based drug developer mentioned information from a separate section Three trial being carried out in Britain was anticipated by the primary quarter of 2021 and might be the idea for regulatory approval, sending its shares up 3.4% in early buying and selling.
Information from an early-to-mid stage or section 2 trial of the vaccine is now anticipated on Friday, the corporate mentioned. Early-stage information had confirmed the vaccine produced excessive ranges of antibodies towards the novel coronavirus.
A handful of firms, together with bigger rivals Pfizer Inc and AstraZeneca Plc, have begun testing their vaccines in late-stage trials, although none of them is but to win regulatory approvals.
Novavax in August mentioned it is going to provide 60 million doses of its coronavirus vaccine candidate to the UK from as early as the primary quarter of 2021.
The corporate can be making ready to ship 100 million doses to the USA by January after it was awarded $1.6 billion for its potential vaccine and has additionally signed provide agreements with Canada and Japan.
(This story has not been edited by NDTV employees and is auto-generated from a syndicated feed.)